外链论坛

 找回密码
 立即注册
搜索
查看: 95|回复: 3

读书笔记丨北京大学肿瘤医院郭军教授团队-中国黑色素瘤原创临床科研周期汇总

[复制链接]

180

主题

0

回帖

9912万

积分

论坛元老

Rank: 8Rank: 8

积分
99120202
发表于 2024-5-17 12:49:57 | 显示全部楼层 |阅读模式

遇见·肿瘤大咖∣ 郭军:“黑老大”死磕黑色素瘤的血性

2020CSCO丨郭军教授:中国黑色素瘤科研初具蓝图,将来需多中心协同推进

盘点2020|斯璐:黑色素瘤治疗发展盘点

解码黑色素瘤青年探索者斯璐:她曾想过放弃

积石成山丨中国黑色素瘤表率性论著周期总结

光荣榜丨中国原创黑色素瘤郭军教授团队历届国际会议大会发言汇总

“路漫漫其修远,吾辈青年当上下求索!”——首届CSCO黑色素瘤专委会青委会成立

历史回顾丨中国临床肿瘤学年度科研发展2015-2021黑色素瘤部分要紧发展+值得关注的发展回顾

● 中国原创黑色素瘤 ●

●●●Original melanoma of China●●●

J Clin Oncol(3篇),Ann Oncol(2篇),Clin Cancer Res(3篇),J Immunother Cancer(2篇),Eur J Cancer(4篇)

中国原创黑色素瘤

Chin J Cancer Res

Chin J Cancer ResA phase II study of fotemustine plus dacarbazine with dendritic cell vaccines as first-line therapy for Chinese patients with advanced acral lentiginous melanoma(2009)

Eur J Cancer

Eur J Cancer  A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients(2011)

J Clin Oncol

J Clin Oncol Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification(2011)

Mol Ther

Mol TherA phase II, randomized, double-blind, placebo-controlled multicenter trial of endostar in patients with metastatic melanoma(2012)

Clin Cancer Res(ChiCTR-TRC-11001798)

Clin Cancer Res Phase II randomized trial comparing high-dose IFN-α2b with Temozolomide plus Cisplatin as systemic adjuvant therapy for resected mucosal melanoma(2013)

Ann Oncol(NCT01028222)

Ann Oncol Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial2017

BMC Cancer(NCT01910181)

BMC CancerVemurafenib in Chinese patients with BRAF V600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study2018

Transl Oncol(KEYNOTE 151)

Transl Oncol A phase Ib study of pembrolizumab as second-line therapy for Chinese patients with advanced or metastatic melanoma(KEYNOTE-1512019

J Clin Oncol(NCT03086174)

J Clin Oncol Axitinib in combination with toripalimab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic mucosal melanoma: an open-label phase IB trial2019

Eur J Cancer(NCT02083354)

Eur J CancerOpen-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma2020

Clin Cancer ResNCT03013101

Clin Cancer ResSafety, efficacy and biomarker analysis of toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial2020

J Immunother CancerCTR20160872

J Immunother Cancer Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study(2020)

J Clin Oncol(NCT02023710)

J Clin Oncol Randomized phase II study of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced mucosal melanoma2021

J Immunother Cancer(NCT03086174)

J Immunother Cancer Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis(2021)

Front Oncol(NCT02083354)

Front Oncol Overall survival of patients with unresectable or metastatic BRAF V600-mutant acral/cutaneousmelanoma administered dabrafenib plus trametinib: long-term follow-up of a multicenter, single-arm phase IIa trial2021

Eur J Cancer(NCT03454919)

Eur J Cancer Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway2021

Melanoma Res(NCT03422445)

Melanoma Res Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy(2022)

J Immunother CancerCTR20140631  and CTR20150881

J Immunother Cancer OrienX010, an oncolytic virus, in patients with unresectable stage IIIC-IV melanoma: a phase Ib study(2022)

Ann Oncol(NCT03178123)

Ann Oncol Toripalimab (anti-PD-1) versus high-dose interferon-α2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial(2022)

BMC Cancer(NCT02738489)

BMC Cancer Safety, activity and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study(2022)

Clin Cancer Res(NCT04091217)

Clin Cancer ResAtezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: a multicenter, open-label, single-arm phase II study(2022)

Eur J Cancer(NCT03932253)

Eur J Cancer A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma(2022)

Front Oncol(KEYNOTE 151

Front Oncol Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study(2022)

整理者

回复

使用道具 举报

31

主题

23

回帖

22万

积分

管理员

Rank: 9Rank: 9Rank: 9

积分
220033
发表于 2024-5-17 13:07:46 | 显示全部楼层
您的帖子让我受益匪浅,我将会尝试您的方法,再次感谢您的分享!
回复

使用道具 举报

185

主题

6

回帖

9911万

积分

论坛元老

Rank: 8Rank: 8

积分
99110129
发表于 2024-5-17 14:15:36 | 显示全部楼层
非常感谢您的回复和分享!我非常欣赏您对于这个项目的热情和承诺。根据您的建议,我已经对我们的计划进行了一些调整,并将在明天给您发送更新。
回复

使用道具 举报

172

主题

6

回帖

9911万

积分

论坛元老

Rank: 8Rank: 8

积分
99110188
发表于 2024-5-17 14:16:49 | 显示全部楼层
敬祈示复,感谢您的回复,期待您的意见。
回复

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

Archiver|手机版|小黑屋|外链论坛 |网站地图

GMT+8, 2024-6-19 08:32 , Processed in 0.071483 second(s), 20 queries .

Powered by Discuz! X3.4

Copyright © 2001-2023, Tencent Cloud.